X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SANOFI INDIA AJANTA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 22.1 36.5 60.5% View Chart
P/BV x 4.2 6.9 61.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 AJANTA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
SANOFI INDIA
Dec-17
AJANTA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,8184,945 36.8%   
Low Rs1,1063,901 28.4%   
Sales per share (Unadj.) Rs239.51,081.8 22.1%  
Earnings per share (Unadj.) Rs52.8141.6 37.3%  
Cash flow per share (Unadj.) Rs59.5185.9 32.0%  
Dividends per share (Unadj.) Rs033.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs230.0868.8 26.5%  
Shares outstanding (eoy) m88.7723.03 385.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.14.1 149.3%   
Avg P/E ratio x27.731.2 88.6%  
P/CF ratio (eoy) x24.623.8 103.3%  
Price / Book Value ratio x6.45.1 124.9%  
Dividend payout %023.3 0.0%   
Avg Mkt Cap Rs m129,782101,862 127.4%   
No. of employees `0006.83.2 209.8%   
Total wages/salary Rs m3,7653,685 102.2%   
Avg. sales/employee Rs Th3,128.47,691.9 40.7%   
Avg. wages/employee Rs Th554.01,137.7 48.7%   
Avg. net profit/employee Rs Th689.71,006.5 68.5%   
INCOME DATA
Net Sales Rs m21,25824,914 85.3%  
Other income Rs m242807 29.9%   
Total revenues Rs m21,49925,721 83.6%   
Gross profit Rs m6,5845,372 122.6%  
Depreciation Rs m5961,022 58.3%   
Interest Rs m411 37.3%   
Profit before tax Rs m6,2265,146 121.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,886 81.6%   
Profit after tax Rs m4,6863,260 143.8%  
Gross profit margin %31.021.6 143.6%  
Effective tax rate %24.736.6 67.5%   
Net profit margin %22.013.1 168.5%  
BALANCE SHEET DATA
Current assets Rs m12,23614,432 84.8%   
Current liabilities Rs m3,4616,010 57.6%   
Net working cap to sales %41.333.8 122.1%  
Current ratio x3.52.4 147.3%  
Inventory Days Days6061 98.9%  
Debtors Days Days8428 296.6%  
Net fixed assets Rs m11,1407,991 139.4%   
Share capital Rs m177230 76.8%   
"Free" reserves Rs m20,23719,778 102.3%   
Net worth Rs m20,41420,008 102.0%   
Long term debt Rs m100-   
Total assets Rs m24,48627,770 88.2%  
Interest coverage x1,519.4468.8 324.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 96.8%   
Return on assets %19.211.8 162.6%  
Return on equity %23.016.3 140.9%  
Return on capital %30.525.8 118.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,6676,306 185.0%   
Fx outflow Rs m1,6165,257 30.7%   
Net fx Rs m10,0521,049 958.2%   
CASH FLOW
From Operations Rs m2,8544,351 65.6%  
From Investments Rs m-2,604-787 330.9%  
From Financial Activity Rs m-2-1,884 0.1%  
Net Cashflow Rs m2481,680 14.8%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 1.6 14.4 10.8%  
FIIs % 7.6 14.6 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 15,184 138.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 22, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS